Trial · NCT07583641
Registered outcomes55
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
41 to 55 of 55
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Secondary | Incidence and prevalence of antibodies against rHuPH20 in plasma over time | up to 24 weeks | rHuPH20 = Recombinant Human Hyaluronidase PH20 |
| Secondary | Change in CASE score in the NMDAR population compared with the non-NMDAR population | up to 24 weeks | CASE = Clinical Assessment Scale in AIE ; NMDAR=N-methyl-D-aspartate receptor. . The CASE (Clinical Assessment Scale in AIE) includes an assessment of 9 items: seizure, memory dysfunction, psychiatric symptoms, consciousness, language problems, dyskinesia/dystonia, gait instability and ataxia, brainstem dysfunction, weakness. This overall CASE total score ranges from 0 to 27, with a higher score indicating a greater degree of disability. |
| Secondary | Change in RBANS total score | week 24 to week 48 | The RBANS (Repeatable Battery for the Assessment of Neuropsychological Status) is a performance outcome measure developed to identify and characterize cognitive impairment by assessing an individual's current level of cognitive performance. |
| Secondary | Percentage of participants with maintained change in the CASE total score (defined as stable or improving) | week 24 to week 48 | The CASE (Clinical Assessment Scale in AIE) includes an assessment of 9 items: seizure, memory dysfunction, psychiatric symptoms, consciousness, language problems, dyskinesia/dystonia, gait instability and ataxia, brainstem dysfunction, weakness. This overall CASE total score ranges from 0 to 27, with a higher score indicating a greater degree of disability. |
| Secondary | Percentage of participants with maintained mRS score (defined as stable or improving) | week 24 to week 48 | The mRS (modified Rankin Scale) is commonly used to measure the degree of disability or dependence in the daily activities of people with neurological disabilities. Scores range from 0 (no symptoms) to 6 (dead). |
| Secondary | Change in NPI-C total score | week 24 to week 48 | The NPI-C (Neuropsychiatric Inventory--Clinician) total score will be used as a global measure of neuropsychiatric symptoms.Total score is calculated by summing the scores of all the individual domains. Each domain score is determined by summing the item scores within that domain. The NPI-C uses a clinician rating method, where ratings for frequency, severity, and caregiver distress are provided for each item. These item scores are then summed to create a total domain score. |
| Secondary | Proportion of participants requiring rescue or second-line AIE therapies | week 24 to week 48 | AIE = Auto-Immune Encephalitis |
| Secondary | Time to participants requiring rescue or second-line AIE therapies | week 24 to week 48 | AIE = Auto-Immune Encephalitis |
| Secondary | Change in CASE | week 24 to week 48 | The CASE (Clinical Assessment Scale in AIE) includes an assessment of 9 items: seizure, memory dysfunction, psychiatric symptoms, consciousness, language problems, dyskinesia/dystonia, gait instability and ataxia, brainstem dysfunction, weakness. This overall CASE total score ranges from 0 to 27, with a higher score indicating a greater degree of disability. |
| Secondary | Change in mRs | week 24 to week 48 | The mRS (modified Rankin Scale) is commonly used to measure the degree of disability or dependence in the daily activities of people with neurological disabilities. Scores range from 0 (no symptoms) to 6 (dead). |
| Secondary | Change in RBANS | week 24 to week 48 | The RBANS (Repeatable Battery for the Assessment of Neuropsychological Status) is a performance outcome measure developed to identify and characterize cognitive impairment by assessing an individual's current level of cognitive performance. |
| Secondary | Time to resolution of status epilepticus | week 24 to week 48 | |
| Secondary | Proportion of participants with seizure freedom for at least the 28 consecutive days preceding the participants in final Part of trial | week 24 to week 48 | mRS=modified Rankin Scale |
| Secondary | Incidence and prevalence of ADA against efgartigimod in serum | week 24 to week 48 | ADA = antidrug antibody(ies) |
| Secondary | Percent change in total IgG levels in serum | week 24 to week 48 | IgG = Immunoglobulin G |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07583641/registered?page=3